Johnson & Johnson Aims for Double-Digit Growth Amid STELARA Biosimilar Competition
Johnson & Johnson (NYSE:JNJ) has raised its growth targets for the year and beyond, forecasting adjusted operational sales growth of 6.5% in 2026 with revenue expected to exceed $100 billion. Despite biosimilar competition threatening STELARA, executives remain confident that new product launches, a robust pipeline including 12 Phase III molecules, and strong performance from existing therapies will drive double-digit growth by the end of the decade. The company plans to outline its long-term strategy in an enterprise business review scheduled for December. CEO Joaquin Duato highlighted progress across three Innovative Medicine areas—oncology, immunology, neuroscience—and MedTech segments like vision and surgery as key drivers. Capital spending is focused on launching new products such as ICOTYDE and the OTTAVA robotic surgical system.
Tickers: $JNJ
Topics: biosimilars growth strategy innovation pipeline pharmaceuticals